Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference

Rhea-AI Summary

Catalyst Biosciences (NASDAQ: CBIO) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recorded presentation will be accessible for registered attendees and on the company's website for 90 days. The company will also engage in 1x1 meetings with investors. Catalyst focuses on addressing unmet needs in rare hematologic and complement-mediated disorders, advancing therapies including MarzAA and DalcA for hemophilia. The company emphasizes ongoing collaborations and potential risks surrounding its pipeline.

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will participate in the Piper Sandler 32^nd Annual Virtual Healthcare Conference taking place December 1-3, 2020. The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site until December 3. It will also be available on the Events and Presentations section on the Company’s website for approximately 90 days.

Catalyst Biosciences will be participating in 1x1 meetings. Investors may request meetings with the management via Piper Sandler.

About Catalyst Biosciences
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare hematologic and complement-mediated disorders. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct – CB2679d-GT – for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about candidates generated by Catalyst’s protease engineering platform having improved functionality and potency, Catalyst’s plans to enroll the first patient in a Phase 3 open-label trial of MarzAA and the Company’s collaboration with Biogen for the development and commercialization of pegylated CB 2782 Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on November 5, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:

Ana Kapor
Catalyst Biosciences, Inc.
investors@catbio.com

FAQ

When is Catalyst Biosciences participating in the Piper Sandler Virtual Healthcare Conference?

Catalyst Biosciences is participating in the Piper Sandler Virtual Healthcare Conference from December 1-3, 2020.

What presentation will Catalyst Biosciences provide during the conference?

Catalyst Biosciences will offer a pre-recorded presentation available for registered attendees and on their website for 90 days.

What are the main product candidates highlighted by Catalyst Biosciences?

Catalyst Biosciences highlights MarzAA and DalcA as main product candidates for hemophilia in its pipeline.

What are the risks mentioned in the Catalyst Biosciences press release?

Risks include potential trial delays, adverse effects, and competition as mentioned in their SEC filings.

How can investors request meetings with Catalyst Biosciences management?

Investors can request meetings with Catalyst Biosciences management via the Piper Sandler conference platform.